Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objectives of this study were to assess the safety and tolerability of LDP-02 in patients
with active Crohn's disease who were not receiving corticosteroids or immunosuppressives, to
assess the ability of LDP-02 to reduce Crohn's disease activity, and to obtain
pharmacokinetic (PK) and pharmacodynamic(PD)information for LDP-02 in patients with active
Crohn's disease.